Author Interview - Professor Andrew Cope, 2026
From The IMID Forum by The Immune-Mediated Inflammatory Disease Forum
March 5, 2026 · 25 min
About this episode
Professor Peter Nash interviews Professor Andrew Cope about his research on long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis.
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.
People in this episode
Host: Professor Peter Nash
Guest: Professor Andrew Cope
Topics covered
- rheumatoid arthritis
- clinical trials
- abatacept
- long-term outcomes
- immune-mediated diseases
Keywords
- rheumatoid arthritis
- abatacept
- clinical trial
- long-term outcomes
- immune-mediated inflammatory diseases
Mentioned in this episode
Organizations: Griffith University, Centre for Rheumatic Diseases, King’s College London
Books & works: Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO)
More episodes of The IMID Forum
- EULAR 2026 Review Podcast · June 12, 2026 · 40 min
- EULAR 2026 Day 4 Highlights Podcast · June 6, 2026 · 5 min
- EULAR 2026 Day 3 Highlights Podcast · June 5, 2026 · 3 min
- EULAR 2026 Day 2 Highlights Podcast · June 4, 2026 · 6 min
- EULAR 2025 Day 1 Highlights Podcast · June 3, 2026 · 6 min
- Discussing RA: Comparative outcomes with upadacitinib in RA · May 28, 2026 · 9 min
Explore listener stats, chart rankings, contacts and more on the The IMID Forum podcast page.